Trade First Wave BioPharma, Inc. - FWBI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.3320 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 2.909 |
| Open* | 2.909 |
| 1-Year Change* | 6.1% |
| Day's Range* | 2.909 - 3.339 |
| 52 wk Range | 2.75-149.80 |
| Average Volume (10 days) | 270.89K |
| Average Volume (3 months) | 14.15M |
| Market Cap | 2.54M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 675.00K |
| Revenue | N/A |
| EPS | -194.33 |
| Dividend (Yield %) | N/A |
| Beta | 1.15 |
| Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 2.9090 | 0.3100 | 11.93% | 2.5990 | 3.0390 | 2.3990 |
| Apr 19, 2024 | 2.5990 | -0.2100 | -7.48% | 2.8090 | 2.9490 | 2.3690 |
| Apr 18, 2024 | 2.8090 | -0.0700 | -2.43% | 2.8790 | 2.8990 | 2.6290 |
| Apr 17, 2024 | 2.7890 | -0.1100 | -3.79% | 2.8990 | 2.9590 | 2.7490 |
| Apr 16, 2024 | 2.9790 | -0.1200 | -3.87% | 3.0990 | 3.2390 | 2.9390 |
| Apr 15, 2024 | 3.1790 | -0.1200 | -3.64% | 3.2990 | 3.4190 | 3.1090 |
| Apr 12, 2024 | 3.2990 | -0.1500 | -4.35% | 3.4490 | 3.4490 | 3.2190 |
| Apr 11, 2024 | 3.3390 | -0.0600 | -1.77% | 3.3990 | 3.5290 | 3.2490 |
| Apr 10, 2024 | 3.4090 | -0.1900 | -5.28% | 3.5990 | 3.5990 | 3.3090 |
| Apr 9, 2024 | 3.5090 | -0.2200 | -5.90% | 3.7290 | 3.7290 | 3.4990 |
| Apr 8, 2024 | 3.7490 | -0.2000 | -5.06% | 3.9490 | 3.9490 | 3.6990 |
| Apr 5, 2024 | 3.9490 | -0.0200 | -0.50% | 3.9690 | 4.0190 | 3.8490 |
| Apr 4, 2024 | 3.9790 | 0.0300 | 0.76% | 3.9490 | 4.0590 | 3.9290 |
| Apr 3, 2024 | 3.9490 | -0.2300 | -5.50% | 4.1790 | 4.3590 | 3.9090 |
| Apr 2, 2024 | 3.8990 | -0.1800 | -4.41% | 4.0790 | 4.1390 | 3.8690 |
| Apr 1, 2024 | 4.1590 | -0.3800 | -8.37% | 4.5390 | 4.5390 | 3.9990 |
| Mar 28, 2024 | 4.3890 | 0.4900 | 12.57% | 3.8990 | 4.5190 | 3.8090 |
| Mar 27, 2024 | 3.9090 | -0.0900 | -2.25% | 3.9990 | 4.0590 | 3.8090 |
| Mar 26, 2024 | 3.9590 | -0.0400 | -1.00% | 3.9990 | 4.0690 | 3.8990 |
| Mar 25, 2024 | 4.1190 | -0.2800 | -6.37% | 4.3990 | 4.3990 | 3.9990 |
First Wave BioPharma, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Sunday, May 12, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q1 2024 First Wave BioPharma Inc Earnings Release Q1 2024 First Wave BioPharma Inc Earnings ReleaseForecast -Previous - |
| Friday, June 21, 2024 | ||
| Time (UTC) 13:00 | Country US
| Event First Wave BioPharma Inc Annual Shareholders Meeting First Wave BioPharma Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 14, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q2 2024 First Wave BioPharma Inc Earnings Release Q2 2024 First Wave BioPharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 12.6781 | 59.0569 | 26.8313 | 14.7437 | 13.4318 |
| Selling/General/Admin. Expenses, Total | 11.9868 | 18.3696 | 7.27976 | 6.04227 | 8.17431 |
| Research & Development | 8.7763 | 38.3204 | 19.105 | 7.85849 | 4.98555 |
| Depreciation / Amortization | 0.015 | 0.048 | 0.84299 | 0.06191 | |
| Other Operating Expenses, Total | -8.08505 | 0 | 0.21 | ||
| Operating Income | -12.6781 | -59.0569 | -26.8313 | -14.7437 | -13.4318 |
| Interest Income (Expense), Net Non-Operating | -0.00746 | -0.01007 | -5.84013 | -0.43394 | -0.10185 |
| Other, Net | -1.94411 | 0.5291 | |||
| Net Income Before Taxes | -14.6296 | -58.5378 | -32.6715 | -15.1777 | -13.5336 |
| Net Income After Taxes | -14.6296 | -58.5378 | -32.6715 | -15.1777 | -13.5336 |
| Net Income Before Extra. Items | -14.6296 | -58.5378 | -32.6715 | -15.1777 | -13.5336 |
| Net Income | -14.6296 | -58.5378 | -32.6715 | -15.1777 | -13.5336 |
| Income Available to Common Excl. Extra. Items | -14.9731 | -84.5186 | -41.7323 | -15.1777 | -13.5336 |
| Income Available to Common Incl. Extra. Items | -14.9731 | -84.5186 | -41.7323 | -15.1777 | -13.5336 |
| Diluted Net Income | -14.9731 | -84.5186 | -41.7323 | -15.1777 | -13.5336 |
| Diluted Weighted Average Shares | 0.71825 | 0.0425 | 0.01354 | 0.01068 | 0.00735 |
| Diluted EPS Excluding Extraordinary Items | -20.8466 | -1988.67 | -3082.15 | -1421.4 | -1840.94 |
| Diluted Normalized EPS | -20.8466 | -1933.33 | -3052.71 | -1421.4 | -1840.94 |
| Revenue | 0 | ||||
| Unusual Expense (Income) | 0 | 2.35199 | 0.39857 | ||
| Total Adjustments to Net Income | -0.34343 | -25.9807 | -9.06087 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 4.18164 | 4.06243 | 2.27967 | -4.38953 | 14.7879 |
| Selling/General/Admin. Expenses, Total | 2.82855 | 2.70074 | 2.17785 | 2.90445 | 6.90451 |
| Research & Development | 1.3531 | 1.36168 | 0.10182 | 0.79107 | 7.88341 |
| Depreciation / Amortization | |||||
| Operating Income | -4.18164 | -4.06243 | -2.27967 | 4.38953 | -14.7879 |
| Interest Income (Expense), Net Non-Operating | -0.00497 | -0.00712 | -0.0015 | 0.0018 | -0.00775 |
| Other, Net | -0.00262 | -0.00111 | -1.70481 | 0 | -0.2393 |
| Net Income Before Taxes | -4.18923 | -4.07065 | -3.98599 | 4.39133 | -15.035 |
| Net Income After Taxes | -4.18923 | -4.07065 | -3.98599 | 4.39133 | -15.035 |
| Net Income Before Extra. Items | -4.18923 | -4.07065 | -3.98599 | 4.39133 | -15.035 |
| Net Income | -4.18923 | -4.07065 | -3.98599 | 4.39133 | -15.035 |
| Total Adjustments to Net Income | -0.09432 | -0.08743 | 0.00207 | -0.15758 | -0.18792 |
| Income Available to Common Excl. Extra. Items | -4.28356 | -4.15808 | -3.98392 | 4.23375 | -15.2229 |
| Income Available to Common Incl. Extra. Items | -4.28356 | -4.15808 | -3.98392 | 4.23375 | -15.2229 |
| Diluted Net Income | -4.28356 | -4.15808 | -3.98392 | 4.23375 | -15.2229 |
| Diluted Weighted Average Shares | 2.27092 | 2.28068 | 0.71825 | 0.23225 | 0.18244 |
| Diluted EPS Excluding Extraordinary Items | -1.88626 | -1.82318 | -5.54671 | 18.2291 | -83.4388 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.88626 | -1.82318 | -5.54671 | 18.2291 | -83.4388 |
| Unusual Expense (Income) | 0 | ||||
| Other Operating Expenses, Total | 0 | 0 | -8.08505 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 3.41276 | 9.42495 | 7.86978 | 3.40829 | 4.8 |
| Cash and Short Term Investments | 1.36291 | 8.24868 | 6.06214 | 0.1758 | 1.11434 |
| Cash | 1.36291 | 8.24868 | 6.06214 | 0.1758 | 1.11434 |
| Short Term Investments | |||||
| Total Receivables, Net | 0.09301 | 0 | 0.55149 | 2.6373 | 3.17268 |
| Prepaid Expenses | 1.95683 | 1.17627 | 1.25615 | 0.59519 | 0.51298 |
| Total Assets | 5.4397 | 11.79 | 12.9239 | 8.90288 | 7.4694 |
| Property/Plant/Equipment, Total - Net | 0.3031 | 0.40931 | 0.09257 | 0.15978 | 0.12885 |
| Goodwill, Net | 1.68418 | 1.91171 | 2.05405 | 1.88669 | 1.92483 |
| Intangibles, Net | 0 | 2.87954 | 3.40708 | 0.57048 | |
| Other Long Term Assets, Total | 0.03966 | 0.04401 | 0.02792 | 0.04105 | 0.04523 |
| Total Current Liabilities | 2.48349 | 12.3004 | 15.5454 | 4.28564 | 2.99552 |
| Payable/Accrued | 0 | 0.53343 | 0.6701 | ||
| Accrued Expenses | 0.38633 | 0.49706 | 0.18443 | 0.15441 | 0.53829 |
| Notes Payable/Short Term Debt | 0.60349 | 0.64124 | 0.55241 | 1.5213 | 0.25503 |
| Other Current Liabilities, Total | 0.77363 | 8.48018 | 13.25 | 0.39299 | |
| Total Liabilities | 2.69755 | 19.6115 | 15.5646 | 4.28564 | 2.99552 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.21406 | 7.31114 | 0.01912 | 0 | 0 |
| Total Equity | 2.74215 | -7.82155 | -2.64069 | 4.61724 | 4.47387 |
| Common Stock | 0.0001 | 0.00149 | 0.00312 | 0.00268 | 0.00177 |
| Additional Paid-In Capital | 171.276 | 147.305 | 93.8349 | 68.5759 | 53.1393 |
| Retained Earnings (Accumulated Deficit) | -168.534 | -153.904 | -95.3662 | -62.6947 | -47.5171 |
| Other Equity, Total | 0 | -1.22414 | -1.11255 | -1.26656 | -1.15011 |
| Total Liabilities & Shareholders’ Equity | 5.4397 | 11.79 | 12.9239 | 8.90288 | 7.4694 |
| Total Common Shares Outstanding | 0.995 | 0.07074 | 0.01483 | 0.01276 | 0.00843 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Property/Plant/Equipment, Total - Gross | 0.34708 | 0.42402 | 0.13097 | 0.4233 | 0.33225 |
| Accumulated Depreciation, Total | -0.04398 | -0.01471 | -0.0384 | -0.26352 | -0.20339 |
| Accounts Payable | 0.72004 | 2.68191 | 1.55859 | 1.68351 | 1.53211 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 3.9766 | 2.35379 | 3.52987 | 3.41276 | 2.54914 |
| Cash and Short Term Investments | 3.29233 | 1.23605 | 2.06444 | 1.36291 | 1.65701 |
| Cash | 3.29233 | 1.23605 | 2.06444 | 1.36291 | 1.65701 |
| Total Receivables, Net | 0 | 0 | 0.02 | 0.09301 | 0.19198 |
| Prepaid Expenses | 0.68427 | 1.11774 | 1.44544 | 1.95683 | 0.56146 |
| Total Assets | 5.92727 | 4.32787 | 5.53398 | 5.4397 | 4.6454 |
| Property/Plant/Equipment, Total - Net | 0.23372 | 0.25713 | 0.28025 | 0.3031 | 0.32567 |
| Property/Plant/Equipment, Total - Gross | 0.29965 | 0.31575 | 0.33155 | 0.34708 | 0.36233 |
| Accumulated Depreciation, Total | -0.06593 | -0.05862 | -0.0513 | -0.04398 | -0.03666 |
| Goodwill, Net | 1.68418 | 1.68418 | 1.68418 | 1.68418 | 1.71479 |
| Intangibles, Net | |||||
| Other Long Term Assets, Total | 0.03277 | 0.03277 | 0.03967 | 0.03966 | 0.0558 |
| Total Current Liabilities | 2.48249 | 3.26125 | 2.62486 | 2.48349 | 6.69416 |
| Accounts Payable | 0.57929 | 1.5912 | 0.46976 | 0.72004 | 3.58299 |
| Accrued Expenses | 0.89986 | 0.54343 | 0.91366 | 0.38633 | 0.33667 |
| Notes Payable/Short Term Debt | 0 | 0.15348 | 0.38039 | 0.60349 | 0 |
| Other Current Liabilities, Total | 1.00334 | 0.97315 | 0.86104 | 0.77363 | 2.77451 |
| Total Liabilities | 2.64846 | 3.44591 | 2.82138 | 2.69755 | 6.92545 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.16597 | 0.18466 | 0.19652 | 0.21406 | 0.23129 |
| Total Equity | 3.27881 | 0.88196 | 2.7126 | 2.74215 | -2.28005 |
| Common Stock | 0.00135 | 0.00042 | 0.00016 | 0.0001 | 0.00023 |
| Additional Paid-In Capital | 183.505 | 177.675 | 175.317 | 171.276 | 163.722 |
| Retained Earnings (Accumulated Deficit) | -180.228 | -176.794 | -172.604 | -168.534 | -164.548 |
| Other Equity, Total | 0 | -1.45472 | |||
| Total Liabilities & Shareholders’ Equity | 5.92727 | 4.32787 | 5.53398 | 5.4397 | 4.6454 |
| Total Common Shares Outstanding | 13.4635 | 4.209 | 1.54958 | 0.995 | 0.32958 |
| Preferred Stock - Non Redeemable, Net | |||||
| Other Current Assets, Total | 0.13868 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.6296 | -58.5378 | -32.6715 | -15.1777 | -13.5336 |
| Cash From Operating Activities | -22.3441 | -32.2882 | -11.2215 | -14.0335 | -10.8693 |
| Cash From Operating Activities | 0.02927 | 0.01471 | 0.0378 | 0.0631 | 0.06191 |
| Amortization | 0 | 0.52755 | 0.52755 | 0.95695 | 0.73654 |
| Non-Cash Items | 2.75792 | 8.60641 | 6.73365 | 1.82513 | 3.57765 |
| Changes in Working Capital | -10.5016 | 17.101 | 14.1509 | -1.70099 | -1.7118 |
| Cash From Investing Activities | 0 | -10.3195 | 0.08735 | -0.0241 | -0.30547 |
| Capital Expenditures | 0 | -0.06949 | -0.00417 | -0.0241 | -0.30547 |
| Cash From Financing Activities | 15.7395 | 44.7635 | 17.0461 | 13.145 | 11.7121 |
| Financing Cash Flow Items | -6.91496 | ||||
| Issuance (Retirement) of Stock, Net | 23.2957 | 44.6747 | 14.1861 | 9.53834 | 11.9028 |
| Issuance (Retirement) of Debt, Net | -0.64124 | 0.08883 | 2.86003 | 3.60664 | -0.19068 |
| Foreign Exchange Effects | -0.25971 | 0.03076 | -0.02559 | -0.02593 | 0.00354 |
| Net Change in Cash | -6.86426 | 2.18654 | 5.88635 | -0.93855 | 0.54087 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Cash Interest Paid | 0.01588 | 0 | 0.10546 | 0.00803 | 0.00401 |
| Other Investing Cash Flow Items, Total | 0 | -10.25 | 0.09152 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -4.07065 | -14.6296 | -10.6437 | -15.035 | -9.62684 |
| Cash From Operating Activities | -2.84558 | -22.3441 | -16.7518 | -12.4977 | -7.91207 |
| Cash From Operating Activities | 0.00732 | 0.02927 | 0.02195 | 0.01464 | 0.00732 |
| Amortization | 0 | 0 | 0 | 0 | 0 |
| Non-Cash Items | 0.37384 | 2.75792 | 0.86545 | 0.75883 | 0.36042 |
| Cash Interest Paid | 0.00899 | 0.01588 | |||
| Changes in Working Capital | 0.84391 | -10.5016 | -6.99554 | 1.76384 | 1.34703 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | 0 | ||
| Cash From Financing Activities | 3.54711 | 15.7395 | 10.2153 | 5.44352 | 5.36715 |
| Financing Cash Flow Items | 0 | -6.91496 | -5.05364 | -2.41496 | -2.41496 |
| Issuance (Retirement) of Stock, Net | 3.77021 | 23.2957 | 15.9102 | 8.3378 | 8.02057 |
| Issuance (Retirement) of Debt, Net | -0.2231 | -0.64124 | -0.64124 | -0.47933 | -0.23847 |
| Foreign Exchange Effects | 0 | -0.25971 | -0.03367 | -0.03952 | -0.00877 |
| Net Change in Cash | 0.70153 | -6.86426 | -6.57017 | -7.09368 | -2.5537 |
| Cash Taxes Paid | |||||
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
First Wave BioPharma, Inc. Company profile
About First Wave BioPharma Inc
First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com